Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients with HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients with HER2+ Breast Cancer in Spain

In the NeoSphere trial, patients with HER2+ breast cancer (BC) treated with neoadjuvant chemotherapy with pertuzumab, trastuzumab and docetaxel (PTD) showed improved pathological complete response (pCR) compared to patients treated with trastuzumab and docetaxel (TD). This benefit is estimated to result in the prevention of 5% relapses at 5-years. The aim of this study was to determine the cost-utility of PTD vs. TD in Spain.